| Previous close | 58.25 |
| Open | 58.26 |
| Bid | 59.20 x 800 |
| Ask | 59.50 x 1100 |
| Day's range | 58.16 - 59.84 |
| 52-week range | 45.76 - 68.34 |
| Volume | 9,835,945 |
| Avg. volume | 10,216,954 |
| Market cap | 134.086B |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings date | 05 Nov 2020 |
| Forward dividend & yield | 1.80 (3.09%) |
| Ex-dividend date | 01 Oct 2020 |
| 1y target est | 73.50 |
- Simply Wall St.
Bristol-Myers Squibb Company (NYSE:BMY) Goes Ex-Dividend Soon
Readers hoping to buy Bristol-Myers Squibb Company (NYSE:BMY) for its dividend will need to make their move shortly...
- Business Wire
Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial
Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial.....
- Motley Fool
FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy
The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.
© 2020 Verizon Media. All rights reserved.
